An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Clinical trial NCT01833039 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT01833039
- Sponsor
- Janssen Biotech, Inc.
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.